Patents Assigned to ONO
  • Publication number: 20110287112
    Abstract: A prostate cancer progression inhibitor comprises 4-(4-cyano-2-{[2-(4-fluoro-1-naphthyl)propanoyl]amino}phenyl)butyric acid, a salt thereof, a solvate thereof, or a prodrug thereof. 4-(4-Cyano-2-{[2-(4-fluoro-1-naphthyl)propanoyl]amino}phenyl)butyric acid is useful as a prostate cancer progression inhibitor because this butyric acid has, for example, a growth inhibiting effect and a hormone responsiveness recovering effect on prostate cancer that has acquired hormone resistance.
    Type: Application
    Filed: January 29, 2010
    Publication date: November 24, 2011
    Applicants: ONO PHARMACEUTICAL CO., LTD., KYOTO UNIVERSITY
    Inventors: Osamu Ogawa, Gozoh Tsujimoto, Eijiro Nakamura, Tomomi Kamba, Yosuke Shimizu, Naoki Terada, Toshiya Kanaji, Takayuki Maruyama
  • Publication number: 20110280878
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Application
    Filed: June 27, 2011
    Publication date: November 17, 2011
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku HONJO, Shiro SHIBAYAMA, Kazuhiko TAKEDA, Masayoshi MATSUO, Takao YOSHIDA, Masakazu MIYAMOTO
  • Patent number: 8053599
    Abstract: The present invention relates to a medicament which is useful for neurodegenerative diseases, which comprises about 1 to about 5 equivalents of a basic metal ion based on 1 equivalent of (2R)-2-propyloctanoic acid or a salt thereof, which is supplied from a metal salt of weak acid or a metal hydroxide, and optionally further comprises an additive. The medicament of the present invention is a medicament which a pH of suitable for intravenous administration, is resistant to fluctuations of the pH and is not clouded when it is dissolved in an infusion, and an injection and the like can be prepared therefrom by using any dissolving liquid and/or dilution liquid.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: November 8, 2011
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Masao Sudoh, Seiichi Tanikawa
  • Patent number: 8039674
    Abstract: Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a substituent(s), or a heterocyclic group which contains at least one nitrogen atom and which may have a substituent(s); n represents 0 to 3, in which when n is 2 or more, a plurality of ring A's may be the same or different from one another); a salt thereof; an N-oxide form thereof; a solvate thereof, a prodrug thereof; and a medicament which includes those. The compound represented by formula (I) is capable of binding S1P receptors (in particular, EDG-1 and/or EDG-6), and useful for preventing and/or treating rejection in transplantation, autoimmune diseases, allergic diseases, etc.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: October 18, 2011
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Hiromu Habashita, Shinji Nakade
  • Patent number: 8026273
    Abstract: An 8-azaprostaglandin represented by formula (I) (wherein all symbols have the same meanings as described in the specification), a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: September 27, 2011
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kousuke Tani, Kaoru Kobayashi, Toru Maruyama, Tohru Kambe, Mikio Ogawa, Tsutomu Shiroya
  • Patent number: 8008449
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: August 30, 2011
    Assignees: Medarex, Inc., Ono Pharmaceutical Co., Ltd.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliana Chen, Josephine M. Cardarelli
  • Patent number: 8008451
    Abstract: Polypeptide produced from human stromal cell line, the process for the preparation of the polypeptide, DNA encoding the polypeptide, vector carrying the DNA, host cell transformed by the vector, antibody of the polypeptide, and pharmaceutical composition containing the polypeptide or the antibody.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: August 30, 2011
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Hideaki Tada, Mikio Konishi, Daikichi Fukushima
  • Publication number: 20110207700
    Abstract: The present invention relates to the compound represented by formula (I): (wherein, all the symbols have the same meaning as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially a digestive system disease caused by stress and is superior to oral absorption.
    Type: Application
    Filed: April 29, 2011
    Publication date: August 25, 2011
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuyuki OHMOTO, Masashi KATO, Yoshifumi KAGAMIISHI, Junichiro MANAKO
  • Patent number: 8003642
    Abstract: The compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof specifically binds CCR5, so it is useful for preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection diabetes cancer metastasis and so on Wherein all symbols in formula are as defined in the specification.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: August 23, 2011
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Shinya Kusuda, Toshihiko Nishiyama, Kazuya Hashimura, Junya Ueda, Shiro Shibayama
  • Patent number: 7998479
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: August 16, 2011
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Patent number: 7998491
    Abstract: The invention discloses a useful and novel factor (polypeptide) which plays an important role for morbid vascular smooth muscle in restenosis after percutaneous transluminal coronary angioplasty (PTCA) and arterial sclerosis in the field of cardiovascular system.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: August 16, 2011
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Kei Tashiro, Kazuhiro Kobuke
  • Patent number: 7991487
    Abstract: For a plurality of combinations of a plurality of operating states included in an operating range of an engine and for a plurality of combinations of a plurality of objective variables, a system, which calculates design variables, includes a calculating device for obtaining global optimal solutions of the design variables that minimize or maximize a sum of the plurality of objective variables, which respectively correspond to the plurality of combinations of the plurality of operating states; a receiving device for receiving designation of an upper limit or a lower limit of the plurality of objective variables; and a searching device for searching for global optimal solutions that result in the smoothest change in the design variables when changing the operating states in a range of the received upper limit to the received lower limit of the objective variables, with one of the global optimal solutions as an initial value set.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: August 2, 2011
    Assignees: Ono Sokki Co., Ltd., The Doshisha
    Inventors: Yoshihiro Hashimoto, Yuichiro Sampei, Tomoyuki Hiroyasu
  • Patent number: 7968572
    Abstract: It is intended to provide a compound represented by the formula (I): wherein all the symbols are as defined in the description; which has a p38 MAP kinase inhibitory activity, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. The compound of the invention is useful for preventing or treating a disease in which the abnormal production of a cytokine such as an inflammatory cytokine or a chemokine or overreaction to them is considered to be involved in the cause and aggravation of pathological conditions, in other words, an inflammatory disease, a respiratory disease, a cardiovascular disease, a central nervous system disease or the like, which is a cytokine-mediated disease.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: June 28, 2011
    Assignee: Ono Pharmaceuticals Co., Ltd.
    Inventors: Hisao Nakai, Shingo Yamamoto, Shingo Nakatani, Tomomi Hirosaki
  • Publication number: 20110152520
    Abstract: A compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof: (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc.
    Type: Application
    Filed: January 28, 2011
    Publication date: June 23, 2011
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshikazu TAKAOKA, Shiro SHIBAYAMA, Rena NISHIZAWA
  • Patent number: 7964726
    Abstract: The present invention relates to the compound represented by formula (I): (wherein, all the symbols has the same meanings as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially a digestive system disease caused by stress and is superior to oral absorption.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: June 21, 2011
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kazuyuki Ohmoto, Masashi Kato, Yoshifumi Kagamiishi, Junichiro Manako
  • Publication number: 20110142856
    Abstract: The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoidarthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
    Type: Application
    Filed: February 15, 2011
    Publication date: June 16, 2011
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaya KOKUBO, Yoshikazu Takaoka, Shiro Shibayama
  • Patent number: 7951816
    Abstract: The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous disease (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: May 31, 2011
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Masaya Kokubo, Yoshikazu Takaoka, Shiro Shibayama
  • Publication number: 20110123550
    Abstract: A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.
    Type: Application
    Filed: July 3, 2009
    Publication date: May 26, 2011
    Applicants: ONO PHARMACEUTICAL CO., LTD., MEDAREX, INC.
    Inventors: Shiro Shibayama, Takao Yoshida, Tamon Hayashi, Akio Hayashi, Jun Murai
  • Patent number: 7947697
    Abstract: 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate of the structural formula (I) has Corticotropin Releasing Factor (CRF) antagonist activity and is useful in treating neuropsychiatric and digestive system diseases.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: May 24, 2011
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Tomoyuki Hasegawa, Toshiaki Matsui, Hiroshi Araki, Tetsuji Saito, Tetsuo Obitsu, Masaki Okamoto, Yuichi Gemba, Yutaka Mikami
  • Publication number: 20110105432
    Abstract: The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. wherein all symbols are described in the specification.
    Type: Application
    Filed: January 7, 2011
    Publication date: May 5, 2011
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromu HABASHITA, Haruto Kurata, Shinji Nakade